Clinical Trial Update: A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) [Phase 3]

View source ↗

Summary

Phase 3 ATLAS trial comparing bevacizumab with or without erlotinib as first-line therapy for non-small cell lung cancer; results have been posted following stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Tarceva (erlotinib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-03-15